The Top 5 Biosimilars Articles for the Week of November 25
The Center for Biosimilars® recaps the top stories for the week of November 25, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 25, 2019.
Number 5: Could there be trouble ahead for Alexion? A Roche subsidiary has claimed that the drug maker infringed on its patent for a technology that extends the half-lives of antibodies.
Number 4: Studies of single-agent immune checkpoint inhibitors in ovarian cancer have shown limited activity, but combination therapy with bevacizumab may hold promise.
Number 3: Researchers report that an unfolding microneedle injector could be a feasible delivery device for biologic drugs like insulin.
Number 2: A new study from the Nordic region shows similar retention rates for patients who start treatment with reference or biosimilar infliximab or etanercept.
Number 1: Data presented during the European Society for Medical Oncology Asia Congress 2019, held last week in Singapore, support the biosimilarity of HLX02 and Herceptin.
Finally, last week, our e-newsletter asked whether you think that we will continue to see more relatively deep discounts on biosimilars’ list prices after Ziextenzo launched at a 37% discount.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim
November 25th 2023A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
